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Abstract
Background—Several observational studies suggested a link between health status and rate of
decline among individuals with Alzheimer’s disease (AD). We sought to quantify the relationship
in a population-based study of incident AD, and to compare global comorbidity ratings to counts
of comorbid conditions and medications as predictors of AD progression.
Design: Case-only cohort study arising from population-based longitudinal study of memory and
aging.
Setting: Cache County, Utah
Participants: 335 individuals with incident AD followed for up to 11 years.
Measurements: Patient descriptors included sex, age, education, dementia duration at baseline,
and APOE genotype. Measures of health status made at each visit included the GMHR (General
Medical Health Rating), number of comorbid medical conditions, and number of non-psychiatric
medications. Dementia outcomes included the Mini-Mental State Exam (MMSE), Clinical
Dementia Rating – sum of boxes (CDR-sb), and the Neuropsychiatric Inventory (NPI).
Results—Health Status tended to fluctuate over time within individuals. None of the baseline
medical variables (GMHR, comorbidities, non-psychiatric medications) were associated with
differences in rates of decline in longitudinal linear mixed effects models. Over time, low GMHR
ratings, but not comorbidities or medications, were associated with poorer outcomes (MMSE: β=
−1.07 p=0.01; CDR-sb: β=1.79 p<0.001; NPI: β=4.57 p=0.01)
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Conclusions—Given that time-varying GMHR, but not baseline GMHR, was associated with
*CORRESPONDING AUTHOR: Jeannie-Marie Leoutsakos, Ph.D., MHS, Assistant Professor, Johns Hopkins University School of
Medicine, Department of Psychiatry, Division of Geriatric Psychiatry and Behavioral Sciences, Bayview – Alpha Commons Building
4th Floor. Baltimore, MD 21224, Phone: 410-550-9884, Fax: 410-550-1407, jeannie-marie@jhu.edu.
†Co-Senior Authors
Conflict of Interest Declaration:





Receives research support from the NIH (NIA:
RAG031348-02S1, R21AG033769; NIMH:
R01MH085740-01A2, R01 MH086881), and the American
Heart Association (09CRP2250944)
None
Ms Han Receives research support from the NIH: AG21136 None
Dr. Mielke Receives research support from the NIH:
AG21136, U01 AG037526
None
Ms. Forrester Receives research support from the NIH: U01 AG037526 None
Dr. Tschanz Receives research support from the NIH: AG21136. None
Dr. Corcoran Receives research support from the NIH: NIA AG21136,
ES 016669, U01 DD 000698, R15 AG 037392, R01 AG
31272
None
Dr. Green Receives research support from the NIH: AG21136 None





None of my financtial affiliations as noted below, are in
conflict. They are reported in interest of full disclosure:
1) Past scientific advisory board for Medivation, Inc.
2) Current contracts with Zinfandel Pharmaceuticals
3) Received funding for travel and speaker honoraria from
Medivation,
Inc., GlaxoSmithKline and Elan Corporation/Wyeth.
4) Has served/serves as an associate editor of
Neuropsychology
Review, on the editorial boards of Alzheimer’s &
Dementia, the Journal
International Neuropsychological Society, and the Journal
of Experimental
and Clinical Neuropsychology, and as a consulting editor
for Aging,
Neuropsychology, and Cognition and Neuropsychology.
5) Holds US Patent #6867236 (issued 2005): Nons-teroidal
Anti-
inflammatory drugs for the treatment of Alzheimer’s
disease.
5) Receives royalties from the publication of Geriatric
Neuropsychology:
Assessment and Intervention (Guildford Publications,
2006).




Dr. Lyketsos •Grant support (research or CME)
-NIMH, NIA, Associated Jewish Federation of Baltimore,
Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai,
Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers,
Novartis, National Football League, Elan
•Consultant/Advisor
-Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest,
Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly,
Pfizer, Genentech, Elan, NFL Players Association, NFL
Benefits Office
•Honorarium or travel support
-Pfizer, Forest, Glaxo-Smith Kline, Health Monitor
None
Leoutsakos et al. Page 2













the outcomes, there is likely a dynamic relationship between medical and cognitive health. GMHR
is a more sensitive measure of health than simple counts of comorbidities or medications. Since
health status is a potentially modifiable risk factor, further study is warranted.
Keywords
Alzheimer; comorbidity; GMHR; disease progression; rate of decline; medical care; cohort study
Introduction
Alzheimer disease (AD) is characterized by cognitive and functional decline and the
presence of neuropsychiatric symptoms, but there is a substantial amount of variability in
rates of decline among individuals with AD (Aguero-Torres et al., 1998; Cortes et al., 2008;
Folstein et al., 1975; Tschanz et al., 2011). Knowing which factors influence rate of decline
will be useful for understanding disease progression and treatment, as well as for resource
planning and prognosis. Previously reported demographic factors associating with rate of
decline include age (Wilkosz et al., 2010) age of dementia onset (Xie et al., 2009), sex
(Tschanz et al.,), education and occupational complexity (Andel et al., 2006; Wilson et al.,
2004). Brain imaging predictors of decline include cerebral atrophy and white matter
hyperintensity burden (Brickman et al., 2008; Mungas et al., 2002). CSF biomarkers of tau
and amyloid have also been shown to predict rate of decline (Buerger et al., 2005); (Kester
et al., 2009). Presence of one or more APOE ε4 alleles has been associated with greater
decline in some studies (Bracco et al., 2007; Martins et al., 2005) but not all (Hoyt et al.,
2005).
While these findings are interesting, these risk factors are not modifiable. For example,
knowing that age is associated with faster decline is not of practical, immediate significance
because we cannot control whether or not people get older. Considering the enormous
burden of AD (Alzheimer’s Association, 2010), identifying modifiable risk factors for more
precipitous decline would have substantial public health impact (Colantuoni et al., 2010).
One potentially modifiable predictor of rate of decline is health status. In one cross-sectional
study, greater medical comorbidity was significantly associated with more severe AD, after
controlling for age and other covariates (Doraiswamy et al., 2002). In another very large
cross-sectional study comparing individuals with AD to demographically matched controls,
individuals with AD had significantly more medical comorbidity and higher medical
expenditures (Kuo et al., 2008). In an earlier nested case-control study in Cache County
comparing individuals with AD to those without, individuals with AD were taking more
medications, were more likely to have a serious illness, and had worse General Medical
Health Ratings (GMHR) (Lyketsos et al., 2005). In a different small cohort study, fast
progressors had significantly more medical diagnoses (6.0 vs. 3.9) than slow progressors
(Boksay et al., 2005). However, in a larger study of 289 ADRC participants, individuals
taking 5 or more medications at baseline declined more slowly than those taking fewer
(Storandt et al., 2002). To date, there have been no longitudinal, population-based studies of
the relationship between health status and AD progression.
This paper aims to characterize the course of health status (as measured by GMHR, number
of non-psychiatric prescription medications, and number of medical comorbidities),
determine whether baseline health status is predictive of cognitive, functional, and
behavioral change, and to examine relationships between time-varying measures of those 3
domains and time-varying measures of health status. This last aim is particularly important,
because it speaks to our ability to alter the course of dementia-related decline through
increased attention to patients’ medical health. The Cache County Dementia Progression
Study (DPS), with its well-characterized, community-based sample of participants, followed
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longitudinally before and after dementia onset, is an ideal setting in which to address these
questions.
Methods
DPS began in 2002, and is a follow-up study of incident cases of dementia identified from
the Cache County Study on Memory in Aging (CCSMA) (Tschanz et al., 2011). The
CCSMA is a longitudinal, population-based study examining the prevalence, incidence, and
risk factors for dementia in Cache County, Utah (Breitner et al., 1999). In its first wave in
1995, the CCSMA enrolled 90% of the 5677 county residents who were aged 65 years or
older. Three subsequent “incidence” waves were completed 1999, 2003, and 2006. 19
incident AD cases were identified during wave 1, 108 in wave 2, 156 in wave 3, and 52 in
wave 4. CCSMA participants diagnosed with incident dementia were followed prospectively
by the DPS, approximately every six months, until death or administrative censoring. As
such, DPS, though a case-only follow-up, can also be considered population-based. These
analyses include DPS participants with a diagnoses of Possible or Probable AD.
Participants and Dementia Diagnoses
Details on the methods used in CCSMA are published elsewhere (Breitner et al., 1999;
Lyketsos et al., 2000). In brief, dementia cases from CCSMA were ascertained via a multi-
stage procedure (Breitner et al., 1999). First, participants were screened for cognitive
disorders using the Modified Mini-Mental State Exam (Teng and Chui, 1987), which was
further adapted for use in epidemiological studies (Tschanz et al., 2002). Individuals who
screened positive, along with a weighted, stratified subsample, were further screened using
an informant-based telephone interview (Kawas et al., 1994). Participants who screened
positive on the interview then underwent a clinical assessment (CA) by a trained research
nurse and psychometrician, which included a structured physical and neurological exam and
a neuropsychological battery (Tschanz et al., 2000). Additional information on each
participant’s medical history, cognitive and functional impairment, and psychiatric
symptoms was obtained from a knowledgeable informant.
Next, a study geriatric psychiatrist and a neuropsychologist reviewed data from the CA and
preliminary diagnoses of dementia were made using DSM-III-R criteria (American
Psychiatric Association, 1987). The age of onset was estimated as the age the individual met
DSM-III-R dementia criteria. Individuals with preliminary dementia diagnoses were then
examined in person by a geriatric psychiatrist and underwent neuroimaging and laboratory
studies for a differential diagnosis of dementia. A panel of experts with expertise in
neurology, geriatric psychiatry, neuropsychology and cognitive neuroscience then reviewed
all data and assigned diagnoses of probable or possible AD according to the NINCDS-
ADRDA criteria (McKhann et al., 1984). Incident cases of dementia identified at CCSMA
waves 1-4 were invited to join the DPS. Institutional review boards at Utah State, Duke, and
the Johns Hopkins Universities reviewed and approved all study procedures.
Demographics
Education and gender were determined at Wave 1 of the CCSMA. APOE genotype was
determined at that time from buccal DNA using previously published methods (Breitner et
al., 1999).
Measures of Dementia Progression and Medical Comorbidity
Trained neuropsychological technicians administered the Mini-Mental State Exam (MMSE),
a measure of global cognitive functioning (Folstein et al., 1975). Scores were adjusted for
items missing due to sensory or motor impairment (Breitner et al., 1999). The Clinical
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Dementia Rating (CDR) (Hughes et al., 1982) measures functional ability in six domains:
memory, orientation, judgment/problem solving, community affairs, participation in home/
hobbies, and personal care. We used the extended version (Dooneief et al., 1996) which
rates subjects on an ordinal scale ranging from 0 (no impairment) to 5 (terminal), producing
a summed score ranging from 0-30. The ratings from 0-3 have the same interpretation as the
traditional CDR, but the additional two categories, profound and terminal, extend the floor
of the measure. Such an extension is important for DPS which follows subjects to death.
CDR was administered by a trained research nurse at each visit, taking into account a
caregiver’s report of symptoms as well as the participant’s performance on
neuropsychological tests. The Neuropsychiatric Inventory (NPI) (Cummings, 1997) assesses
neuropsychiatric symptoms (NPS) that commonly occur in dementia, including delusions,
hallucinations, agitation, aggression, depression, apathy, elation, anxiety, disinhibition,
irritability, and aberrant motor behavior. The instrument first screens for symptoms in each
domain. If positive, NPI rates the individual by frequency (0-3) and severity (0-4).
Individuals currently on antipsychotic medication for either hallucinations or delusions
automatically received severity scores of 4 for that domain. Those two scores are then
multiplied to obtain scores for each domain (0-12), and then summed across all 12 domains
for a total score ranging from 0-120).
At each visit, participants were asked whether they had used any prescription medications in
the previous 2 weeks. If they answered yes, they were asked to produce the medication
containers and, for each, the name, indication, strength, dosage form, age at first use, and
duration of use was recorded. The list of medical comorbidities or events specifically
assessed by targeted questions included asthma, emphysema, bronchitis, pneumonia,
transient ischemic attack, cerebrovascular accident, MI, Parkinson’s disease, epilepsy,
hypertension, hypercholesteremia, diabetes, coronary artery bypass graft, angioplasty,
headache, chronic pain, head injury, brain injury, arthritis, ulcers, constipation, thyroid
conditions, cancer, and angina. The first four were assessed only at baseline; the remaining
conditions were also reassessed at each follow-up visit.
The General Medical Health Rating (GMHR) is a rapid bedside global rating of health status
in dementia patients (Lyketsos et al., 1999). Ratings are derived from an interview of the
patient and their caregiver, including current and past medical history and a review of
systems. To receive a rating of 4 (excellent), patients typically have no unstable illnesses, no
more than 2 stable illnesses, and are on no more than 2 medications. To receive a rating of 3
(good), patients typically have one unstable but treated illness, no more than 4 stable
illnesses and are on no more than 4 medications. To receive a rating of 2 (fair), patients
typically have no more than 3 unstable illnesses. Very ill patients receive a rating of 1
(poor). It is important to note that these are only rules of thumb, and the clinician’s overall
general impression plays a significant role in determination of the rating. The GMHR has
demonstrated excellent inter-rater reliability (weighted kappa = 0.93) and has been shown to
be a stronger predictor of mortality than either age or dementia severity (Lyketsos et al.,
1999).
Statistical Analysis
Descriptive analyses of demographics, medical variables, and outcomes were performed to
test distributional assumptions of the proposed analyses. Time was measured in years from
the baseline visit. All longitudinal regression models included random effects for both
intercept and time (Laird, 1982). We chose random effects models over the method of
generalized estimating equations (GEE), as the latter entails an assumption that all loss to
follow-up occurs completely at random. In the present study, we expected loss-to-follow up
to be more likely among individual who are older or in poorer health, and therefore not
completely at random. In reporting findings from these models, when we refer to “decline”,
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this will refer to worsening of symptoms, not necessarily numerical decreases in scale
scores, as increases in both CDR and NPI scores imply greater severity.
The first set of analyses examined change in MMSE, CDR-SB, and NPI total as a function
of baseline GMHR rating. GMHR at baseline was included as a set of two binary covariates
(4-excellent, 3-good, 2/1-fair/poor). GMHR values of 1 and 2 were combined due to the
very small number of individuals with ratings of 1. A value of 4 (representing excellent
health) was the reference group. Interactions between GMHR and time (measured in years)
were also included. For example, the interaction between time and the GMHR=3 indicator
variable represents the expected difference in rate of change between two individuals, one
with a baseline GMHR of 3 and one with a baseline GMHR of 4. . Previous DPS analyses
had demonstrated that the trajectories of many individuals were not straight lines, but
instead typically appeared to curve downward over time. (Tschanz et al., 2011). To
appropriately model this downward curvature, we included a quadratic (time-squared) term,
and terms for its interaction with GMHR,in each of the models. We used likelihood ratio
tests to compare models with and without these quadratic terms (Casella, 2002). Previous
DPS analyses have reported associations between MMSE, CDR-sb, and NPI totals and the
following variables: baseline age, male sex, years of education, dementia duration at
baseline visit, and presence of one or more APOE ε4 alleles. These variables were therefore
included in all models. Analogous models were also fit using number of baseline comorbid
medical conditions, number of baseline non-psychiatric prescription medication and both,
rather than GMHR.
The second set of models used time-varying measurements of health status as predictors of
changeon each outcome. Using time-varying covariates allows for estimation of the effects
of those measurements on the outcome variables as measured at each visit (e.g., not lagged),
rather than on overall rate of decline. As before, linear and quadratic time terms were
included, but interactions between the time variables and the health measures were not
included. Analyses were conducted using STATA Version 11.1 (Stata Corp LP, 2009).
We conducted post-hoc power analyses based on the formulae of Jung and Ahn (2003),
because they account for missing data due to attrition. Based on these formulae and
attributes of our observed data, we would expect to have 80% power to detect a between-
GMHR group difference in rate of decline of 0.79 points per year. Details of the power
calculations are available from the first author on request.
Results
All 335 individuals with incident possible or probable AD and without a vascular dementia
component who were identified as part of the 4 waves of CCSMA were included in these
analyses. The means and standard deviations of the baseline scores on the three outcomes
were MMSE: 21.96 (4.62), CDR-sb: 5.93 (3.39), and NPI: 4.66 (9.25). Of the 335
participants, 70 (21%) were still active (alive and completing visits) at the time of study
close. During the study, 217 (65%) individuals died and 48 (14%) moved away or withdrew
from the study. Of the 335 participants, 105 (31.3%) had only one study visit. Among the
230 with at least one follow-up visit, the total number of visits ranged from 2 to 13 with a
median of 4.The lengths of observation ranged from 0.65 to 11.18 years with a median of
3.07 years. Table 1 shows mean number of years of follow-up by presence or absence of
each dichotomous baseline variable or tertile of each continuous variable. As anticipated,
both GMHR and age were significantly associated with length of follow-up time. There was
no clear relationship between length of follow-up and education, dementia duration, number
of medical comorbidities, or medications at baseline.
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There was considerable variability (both up and down) in GMHR over time within
individuals. At the second visit, of the 226 subjects for whom we had GMHR ratings at both
visits 1 and 2, 135 (60%) had the same rating as they had at visit 1, 26 (12%) had gotten
worse, and 65 (28%) had improved. At the third visit, of the 149_subjects for whom we had
GMHR ratings at both visits 2 and 3, 100 (67%) had the same rating as they had at visit 2,
32 (21%) had gotten worse, and 17 (11%) had improved.
Ordinal logistic regression models demonstrated modest, but statistically significant
associations between baseline GMHR and number of comorbidities (p<0.001, pseudo-
r2=0.08) and number of non-psychiatric prescription medications (p<0.001, pseudo-
r2=0.03). Pseudo-r2 values represent scaled improvements in log likelihood values of the
models with predictors as compared to a model with only an intercept (Agresti, 1999).
Table 2 shows results from the first set of models used to determine the effect of baseline
GMHR rating on decline. For each of the three outcomes, likelihood ratio tests suggested
that quadratic time effects were not needed. Both time and dementia duration were
significantly associated with worse scores on all three outcomes. Baseline GMHR ratings of
1 (poor) or 2 (fair) were significantly associated with higher (worse) CDR-sb scores, as
compared to individuals with a baseline GMHR rating of 4, implying that, on average,
individuals with GMHR ratings of 1 or 2 had CDR-sb scores which were approximately one
and a half points higher than individuals with GMHR ratings of 4. Older age at baseline was
associated with lower MMSE,, and higher CDR-sb scores. Male sex was associated with
lower MMSE and higher education was associated with higher MMSE. There were no
statistically significant interactions between GMHR and time, suggesting that baseline
GMHR ratings are not predictive ofsubsequent rate of decline.
Table 2 also shows models with number of comorbid medical conditions and number of
non-psychiatric medications as predictors of change in AD outcomes. The model for NPI
total contains only a random effect for the intercept, as the model with random effects for
both intercept and time failed to converge. For all three outcomes, likelihood ratio tests
showed that the time-squared terms were necessary. Therefore these terms were retained,
even when they were not individually statistically significant. Both time and dementia
duration were statistically significantly associated with lower scores on all three outcomes.
Older age at baseline was associated with lower MMSE, and higher CDR-sb scores. Male
sex was associated with lower MMSE and higher education was associated with higher
MMSE. With the exception of the interaction between number of comorbid medical
conditions and time-squared for MMSE, neither comorbidities nor medications appeared to
be associated with differences in rates of decline.
The next set of models, shown in table 3, used GMHR as a time-varying covariate. All 3
outcomes were statistically significantly associated with time and time-squared. For the
MMSE and CDR-sb, individuals declined over time, and the mean rate of decline increased
with time. For the NPI, the positive time term but negative time-squared term suggests that
NPI worsens over time, but that this worsening slows, or levels out, over the course of
illness. As in the previous models, longer dementia duration was associated with worse
ratings on all 3 outcomes. Male sex was associated with worse MMSE scores but better
CDR-SB scores. For all 3 outcomes, having a GMHR of 1 or 2 (fair or poor) was
statistically significantly associated with worse ratings.
Table 3 shows results from a similar set of models, but with number of medical
comorbidities and number of non-psychiatric medications as time-varying covariates. The
parameter estimates show a similar pattern to the time-varying GMHR analyses in table 3,
with time and time-squared being statistically significantly associated with all three
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outcomes, and with accelerating decline for both MMSE and CDR-Sum, but decelerating
decline (amelioration of worsening) for NPI total.
Discussion
In this population-based longitudinal study, health status (as measured by the GMHR)
appeared to fluctuate over time for many of the participants, rather than decline
monotonically. This may explain why baseline measures of health were not clear predictors
of rates of dementia progression, and also suggests that GMHR may be a risk factor that can
be altered, thus altering the course of patients’ AD-related decline. GMHR at baseline was
only associated with CDR-sb scores, and was not associated with rate of decline on any of
the three outcomes. Neither number of comorbidities nor number of non-psychiatric
medications at baseline was associated with decline on any of the three domains. By
contrast, having a GMHR of 1 or 2 at a DPS visit was strongly associated with worse scores
in all 3 domains at that same visit, though this was not true for medications or comorbidities.
This suggests that GMHR, whose scoring is only partly based on number of comorbidities
and medications, is capturing something above and beyond just simple counts. It further
suggests that there is a dynamic relationship between medical and cognitive health, since the
effect appears to be immediate and GMHR fluctuates in a substantial portion of the sample.
The literature on the relationship between general medical health and dementia is somewhat
sparse. The majority of papers to date describe cross-sectional studies. Of the two previously
published cohort studies, one found that fast progressors had significantly more
comorbidities (Boksay et al., 2005), while the second found that a larger number of
medications was associated with slower decline (Storandt et al., 2002). We found no
associations between decline in any domain with either comorbidities or prescriptions, as
measured at baseline. Neither study reported on health variables measured longitudinally.
For the most part, our findings confirmed previously reported risk factors for poorer
outcomes, including older age and greater dementia duration at baseline. Female sex is
generally associated with worse prognosis; we found that female sex was associated with
higher MMSE scores but worse CDR-sb scores. Several studies have found an association
between higher education and poorer outcomes, but in our sample we found associations
with higher scores on MMSE, and no associations with either CDR or NPI. Contrary to
some published reports, presence of one or more APOE-4 alleles was not significantly
associated with any of the outcomes in either the baseline or time-varying models.
The strengths of this study include its population-based cohort and its capture of incident
cases, thus allowing for observation over the full course of illness. The high participation
rates and longevity of Cache County residents (Tschanz et al.,2011) serve to reduce potential
biases as a result of selection or competing risks. Another strength is the wealth of
information collected, including measures of dementia progression in 3 domains, detailed
health status assessment, and medication use data.
Potential limitations include the lack of follow-up in approximately one third of the sample
and the association between low GMHR and shorter follow-up time. This association likely
resulted in estimates of associations between poor health and faster dementia progression
that were biased toward the null hypothesis, as the sicker individuals were less likely to be
observed. Hence our findings of an association between GMHR ratings and dementia
progression are probably conservative. Health status is complex and difficult to measure,
particularly because it is a dynamic process. Though it has demonstrated excellent reliability
and validity the GMHR is a global measure, that does not allow for differential weightings
of conditions that may have a greater or lesser impact on health status as other ratings do. In
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the majority of follow-up visits, CDR and GMHR ratings were performed by the same
nurse, thus introducing the possibility that scores on one instrument influenced scores on the
other. This study only enrolled individuals aged ≥ 65, therefore these findings may not apply
to those with early onset AD. The Cache County population is predominantly white, well-
educated, and of northern European descent, thus potentially limiting the generalizability of
the findings to other populations. Further, the majority of the study sample belongs to the
Church of Jesus Christ of Latter Day Saints, which prohibits tobacco, caffeine, and alcohol
use, thus limiting our ability to assess the effects of these substances on dementia
progression. This may also have altered the relationship between dementia progression and
medical comorbidities known to be associated with these behaviors, such as cardiovascular
disease and certain cancers (Breitner et al., 1999). Despite this potential limitation, atrial
fibrillation, systolic hypertension, and angina have been associated with faster decline on
MMSE and CDR-sb in this sample (Mielke et al., 2007).
Our findings show that health status, as measured by GMHR, can fluctuate both up or down,
and they suggest that the course of decline might be improved through better medical care.
This lends additional support to recent recommendations and practice guidelines calling for
increased attention to general medical care among individuals with AD (Lyketsos et al.,
2006; Lyketsos, 2012; Rabins et al., 2006). One potential barrier to this is the fragmentation
and lack of continuity of health care provision in the US (Bartels, 2003). One solution is the
adoption of more collaborative models of care; several recent studies have demonstrated
their efficacy in improving some outcomes (Callahan et al., 2011; Counsell et al., 2007;
Vickrey et al., 2006) without additional net costs (Counsell et al., 2009).
It is important to note that while we have demonstrated an association between GMHR and
dementia progression, we have not demonstrated a causal relationship. Establishing such a
relationship in an observational study is difficult, in part because it is not possible to
determine the temporal order in cases where both medical and cognitive declines (or gains)
occurred between study visits. It is reasonable to suggest that poorer physical health would
lead to poorer cognitive/mental health by placing an additional stressor on the brain, but the
reverse is also plausible. Poorer cognition and function or increased psychiatric symptoms
could lead to physical decline through self-neglect, improper medication administration and
monitoring of chronic conditions such as diabetes or asthma, decreased access to health
services, or decreased social and physical activity. It is likely that mechanisms in both
directions are at work. Given the paucity of potentially modifiable factors affecting the
course of dementia, further study of this relationship is warranted.
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Table 2
Baseline GMHR, Non-Psychiatric Medications, Comorbidities, and AD Outcomes
MMSE CDR-sb NPI-Total
Baseline GMHR Model
Time −1.82 (0.38)* p<0.001 1.51 (0.28) p<0.001 2.23 (0.82) p<0.01
GMHR=1 or 2 −1.26 (0.84) p=0.13 1.50 (0.58) p=0.01 4.78 (2.66) p=0.07
GMHR=3 0.55 (0.78) p=0.48 −0.41 (0.54) p=0.45 2.37 (2.48) p=0.34
GMHR=1/2 x time 0.23 (0.46) p=0.61 −0.51 (0.34) p=0.13 0.93 (1.05) p=0.38
GMHR=3 x time −0.10 (0.42) p=0.82 −0.06 (0.30) p=0.84 0.11 (0.90) p=0.90
Baseline Age −0.12 (0.04) p<0.01 0.06 (0.03) p=0.05 −0.14 (0.12) p=0.25
Male −1.07 (0.52) p=0.04 −0.65 (0.35) p=0.07 0.14 (1.51) p=0.92
Education 0.24 (0.08) p=0.004 0.03 (0.06) p=0.65 0.02 (0.24) p=0.94
Dementia Duration −1.18 (0.20) p<0.001 1.04 (0.14) p<0.0001 1.65 (0.58) p<0.01
APOE-4 Alleles 0.70 (0.50) p=0.16 −0.05 (0.34) p=0.88 2.05 (1.46) p=0.16
Baseline Medications and Comorbidities Model
Time −2.16 (0.33)* p<0.001 1.5 (0.26) p<0.001 4.13 (1.07) p<0.001
Time Squared 0.00 (0.04) p=0.97 0.02 (0.03) p=0.41 −0.29 (0.13) p=0.25
Medications 0.02 (0.06) p=0.79 0.01 (0.04) p=0.86 0.09 (0.22) p=0.67
Comorbidities 0.09 (0.14) p=0.51 −0.11 (0.10) p=0.28 0.25 (0.50) p=0.61
Med. x Time 0.03 (0.04) p=0.41 −0.02 (0.03) p=0.49) 0.08 (0.14) p=0.57
Med. x Time2 0.00 (0.01) p=0.73 0.00 (0.01) p=0.99 −0.02 (0.02) p=0.38
Comorb. x Time 0.13 (0.09) p=0.15 −0.11 (0.07) p=0.15 −0.28 (0.30) p=0.35
Comorb. x Time −0.02 (0.01) p=0.04 0.010 (0.10) p=0.16 0.05 (0.04) p=0.25
Baseline Age −0.13 (0.04) p=0.001 0.61 (0.03) p=0.03 −0.02 (0.12) p=0.88
Male −1.08 (0.53) p=0.04 −0.53 (0.36) p=0.15 −0.32 (1.49) p=0.83
Education 0.26 (0.08) p=0.002 −0.01 (0.06) p=0.80 −0.10 (0.23) p=0.66
Dementia Duration −1.20 (0.20) p<0.001 1.122 (0.14) p<0.000 1.83 (0.55) p=0.001
APOE-4 Alleles −0.64 (0.51) p=0.21 −0.13 (0.35) p=0.71 2.21 (1.41) p=0.12
*
beta coefficient (standard error), p-value
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Table 3
Time-Varying GMHR, Non-Psychiatric Medications, Comorbidities and AD Outcomes
MMSE CDR-sb NPI-Total
Time-Varying GMHR Model
Time −1.65 (0.16)* p<0.001 1.19 (0.13) p<0.001 4.01 (0.56) p<0.001
Time Squared −0.04 (0.02) p=0.03 0.04 (0.02) p=0.01 −0.25 (0.08) p=0.001
GMHR=1 or 2 −1.07 (0.42) p=0.01 1.79 (0.34) p<0.001 4.57 (1.80) p=0.01
GMHR=3 0.01 (0.34) p=0.98 0.26 (0.28) p=0.35 1.83 (1.49) p=0.22
Baseline Age −1.22 (0.04) p=0.002 0.05 (0.03) p=0.10 −0.09 (0.12) p=0.43
Male −1.06 (0.52) p=0.04 −0.70 (0.35) p=0.05 −0.16 (1.49) p=0.91
Education 0.24 (0.08) p=0.004 0.03 (0.06) p=0.59 −0.01 (0.24) p=0.98
Dementia Duration −1..22 (0.19) p<0.001 1.07 (0.13) p<0.001 1.76 (0.57) p=0.002
APOE-4 Alleles −0.69 (0.50) p=0.16 −0.08 (0.34) p=0.82 2.34 (0.44) p=0.11
Time-Varying Medications and Comorbidities
Time −1.60 (0.17)*p<0.001 1.05 (0.13) p<0.001 3.75 (0.54) p<0.001
Time Squared −0.05 (0.02) p=0.02 0.06 (0.02) p<0.001 −0.26 (0.07) p<0.001
Medications 0.01 (0.04) p=0.86 0.01 (0.03) p=0.78 0.80 (0.15) p=0.61
Comorbidities −0.05 (0.08) p=0.57 −0.03 (0.07) p=0.66 −0.11 (0.32) p=0.73
Baseline Age −0.13 (0.04) p=0.001 0.06 (0.03) p=0.02 −0.02 (0.12) p=0.84)
Male −0.91 (0.53) p=0.09 −0.68 (0.37) p=0.06 −0.32 (1.47) p=0.83
Education 0.24 (0.08) p=0.004 −0.01 (0.06) p=0.91 −0.12 (0.23) p=0.62
Dementia Duration −1.19 (0.20) p<0.001 1.12 (0.14) p<0.001 1.83 (0.55) p=0.001
APOE-4 Alleles −0.63 (0.51) p=0.22 −0.12 (0.35) p=0.73 2.16 (1.41) p=0.12
*
beta coefficient (standard error), p-value
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